Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9C8KQ)

Drug Name
Lauric Acid Drug Info
Synonyms
lauric acid; DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3893
ChEBI ID
CHEBI:30805
CAS Number
CAS 143-07-7
TTD Drug ID
DM9C8KQ
INTEDE Drug ID
DR2290

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Hepatocyte nuclear factor 4-alpha (HNF4A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [13]
BI6015 DMRXK5G Discovery agent N.A. Investigative [14]
Drug(s) Targeting Group IIA phospholipase A2 (GIIA sPLA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KH064 DMR1NYF Breast cancer 2C60-2C65 Clinical trial [15]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [2]
2-Propanol, Isopropanol DML5O0H Discovery agent N.A. Investigative [13]
2-(4-phenoxyphenoxy)ethanamine DM7TBUJ Discovery agent N.A. Investigative [16]
CACOSPONGIONOLIDE DMIPJUS Discovery agent N.A. Investigative [17]
Elaidoylamide DMP8VDT Discovery agent N.A. Investigative [2]
Cacospongionolide E DM2DYAV Discovery agent N.A. Investigative [17]
N-Tridecanoic Acid DMNZ37C Discovery agent N.A. Investigative [13]
CACOSPONGIONOLIDE B DMCSXNW Discovery agent N.A. Investigative [17]
BOLINAQUINONE DMVB6UG Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Lymphocyte antigen 96 (LY96)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [13]
3-Hydroxy-Myristic Acid DMFJLWO Discovery agent N.A. Investigative [2]
Drug(s) Targeting Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Decanoic Acid DM8FMYL Discovery agent N.A. Investigative [2]
2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE DM60AJ2 Discovery agent N.A. Investigative [13]
Caprylic acid DMLGS82 Discovery agent N.A. Investigative [19]
Drug(s) Targeting Lactotransferrin (LTF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Parecoxib DMIV8CT N. A. N. A. Phase 4 [13]
Talactoferrin DMV7T64 Diabetic foot ulcer BD54 Phase 3 [20]
HLF 1-11 DMDFG1O Bacteremia 1A73 Phase 1/2 [21]
Nimesulide DMR1NMD Metastatic colorectal cancer 2B91 Terminated [22]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [2]
Fucose DMAHMSV N. A. N. A. Investigative [2]
Alpha-D-Fucose DM6VH7A Discovery agent N.A. Investigative [2]
Nitrilotriacetic Acid DMIOQFU Discovery agent N.A. Investigative [2]
3h-Indole-5,6-Diol DMBFCTZ Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Virus Genome polyprotein (Viru POL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [13]
Drug(s) Targeting Toll-like receptor 4 (TLR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MPL-containing Pollinex allergy desensitization vaccine DMXSDJU Allergy 4A80-4A85 Preregistration [23]
Cadi-05 DMPTCYB Prostate cancer 2C82.0 Phase 3 [24]
Resatorvid DMFMWYC Sepsis 1G40-1G41 Phase 3 [25]
ERITORAN DMKQZ0L Sepsis 1G40-1G41 Phase 3 [26]
G100 DMKHNXA Non-hodgkin lymphoma 2B33.5 Phase 2 [27]
OM-174 DM2THBX Solid tumour/cancer 2A00-2F9Z Phase 1 [28]
NI-0101 DM31FOP Autoimmune diabetes 5A10 Phase 1 [29]
GSK1795091 DMC6QE4 Solid tumour/cancer 2A00-2F9Z Phase 1 [27]
CRX-675 DMHDSYF Hepatitis virus infection 1E50-1E51 Phase 1 [29]
CS-4771 DMVDLT4 Sepsis 1G40-1G41 Discontinued in Phase 1 [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Thiolactomycin DMBAWDG Malaria 1F40-1F45 Investigative [31]
PLATENSIMYCIN DM9N0RH Bacterial infection 1A00-1C4Z Investigative [13]
Drug(s) Affected By Transcription factor p65 (RELA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [32]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [33]
Selenium DM25CGV N. A. N. A. Approved [34]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [35]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [36]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Peroxisome proliferator-activated receptor alpha (PPARA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [42]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [44]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [45]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [46]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [47]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [48]
Testosterone DM7HUNW Hot flushes GA30 Approved [49]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [50]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [52]
Fructose DM43AN2 Vomiting MD90 Approved [53]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [54]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [55]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [56]
Ketotifen DM74XKS Allergic conjunctivitis 9A60.02 Approved [57]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [10]
Leflunomide DMR8ONJ Arthritis FA20 Approved [58]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [59]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [60]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [61]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [62]
Capsaicin DMGMF6V Back pain ME84.Z Approved [63]
Zafirlukast DMHNQOG Asthma CA23 Approved [64]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [61]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [65]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [62]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [66]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [67]
Theophylline DMRJFN9 Bronchitis CA20 Approved [68]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [69]
Ethanol DMDRQZU Chronic pain MG30 Approved [70]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [71]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [72]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [73]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [68]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [74]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4Z1 (CYP4Z1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [75]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [75]
20-HETE DM5BAJ9 Discovery agent N.A. Investigative [8]
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [8]
Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [76]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [77]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [77]
Methotrexate DM2TEOL Anterior urethra cancer Approved [42]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [78]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [79]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [79]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [77]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [77]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [77]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) TTRFV0W FABF_ECOLI Inhibitor [2]
Group IIA phospholipase A2 (GIIA sPLA2) TTO8QRU PA2GA_HUMAN Inhibitor [2]
Hepatocyte nuclear factor 4-alpha (HNF4A) TT2F3CD HNF4A_HUMAN Inhibitor [2]
Lactotransferrin (LTF) TTSZDQU TRFL_HUMAN Inhibitor [2]
Lymphocyte antigen 96 (LY96) TT8S9AV LY96_HUMAN Inhibitor [2]
Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) TTPH97Y FAB1_MYCTU Inhibitor [2]
Toll-like receptor 4 (TLR4) TTISGCA TLR4_HUMAN Inhibitor [2]
Virus Genome polyprotein (Viru POL) TTVBE0F POLG_HRV1A Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 107L2 (cyp107) Main DME DECT13Q PIKC_STRVZ Substrate [3] , [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Biotransformations [5]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Regulation of Drug Effects [6]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Regulation of Drug Effects [7]
Cytochrome P450 4Z1 (CYP4Z1) OTKRGJBG CP4Z1_HUMAN Regulation of Drug Effects [8]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Protein Interaction/Cellular Processes [9]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Gene/Protein Processing [10]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Gene/Protein Processing [11]
UDP-glucuronosyltransferase 1A3 OTUEOER3 UD13_HUMAN Biotransformations [12]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5534).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
4 Structural insights into the binding of lauric acid to CYP107L2 from Streptomyces avermitilis. Biochem Biophys Res Commun. 2017 Jan 22;482(4):902-908.
5 Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. doi: 10.1124/mol.60.2.382.
6 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
7 CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 2006 Jun 12;580(14):3361-7.
8 Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012 Oct 1;264(1):73-83. doi: 10.1016/j.taap.2012.07.019. Epub 2012 Jul 25.
9 Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun. 1999 Jul 14;260(3):609-13. doi: 10.1006/bbrc.1999.0951.
10 A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
11 Inhibition of Nod2 signaling and target gene expression by curcumin. Mol Pharmacol. 2008 Jul;74(1):274-81. doi: 10.1124/mol.108.046169. Epub 2008 Apr 15.
12 In vitro studies in microsomes from rat and human liver, kidney, and intestine suggest that perfluorooctanoic acid is not a substrate for microsomal UDP-glucuronosyltransferases. Drug Chem Toxicol. 2005;28(3):281-7. doi: 10.1081/dct-200064468.
13 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
14 HNF4alpha antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem Biol. 2012 Jul 27;19(7):806-18.
15 D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
16 Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
17 A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
18 New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
19 Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35.
20 Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
21 The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
22 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
23 Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
24 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
25 Clinical pipeline report, company report or official report of Takeda (2009).
26 Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28 Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
30 Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
31 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
32 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
33 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
34 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
35 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
36 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
37 Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
38 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
39 Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
40 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
41 Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
42 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
43 The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.
44 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
45 Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):204-9. doi: 10.1093/abbs/gmq130. Epub 2011 Jan 21.
46 Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
47 Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol. 2008 Mar;73(3):968-76. doi: 10.1124/mol.107.036780. Epub 2007 Dec 13.
48 (9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells. Toxicology. 2014 Dec 4;326:18-24.
49 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
50 Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009 Sep;29(9):3647-58.
51 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
52 Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
53 Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
54 Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
55 AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
56 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
57 Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
58 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
59 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
60 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
61 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
62 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
63 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
64 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
65 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
66 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
67 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
68 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
69 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
70 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
71 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
72 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
73 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
74 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
75 Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Arch Biochem Biophys. 2005 Apr 15;436(2):377-85. doi: 10.1016/j.abb.2005.02.022.
76 Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
77 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
78 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
79 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.